DHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization
Contemporary Clinical Trials · 2024
DOI: 10.1016/j.cct.2024.107633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2024. Verfasst von Xiaosong Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: xshi2@kumc.edu. Hauptthemen laut MEDLINE: Bayes Theorem, Premature Birth, Docosahexaenoic Acids, Dietary Supplements. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Early preterm birth (ePTB) - born before 34 weeks of gestation - poses a significant public health challenge. Two randomized trials indicated an ePTB reduction among pregnant women receiving high-dose docosahexaenoic acid (DHA) supplementation. One of them is Assessment of DHA on Reducing Early Preterm Birth (ADORE). A survey employed in its secondary analysis identified women with low DHA levels, revealing that they derived greater benefits from high-dose DHA supplementation. This survey's inclusion in future trials can provide critical insights for informing clinical practices. OBJECTIVE: To optimize a Phase III trial design, ADORE Precision, aiming at assessing DHA supplement (200 vs. 1000 mg/day) on reducing ePTB among pregnant women with a low baseline DHA. METHODS: We propose a Bayesian Hybrid Response Adaptive Randomization (RAR) Design utilizing a finite mixture model to characterize gestational age at birth. Subsequently, a dichotomized ePTB outcome is used to inform trial design using RAR. Simulation studies were conducted to compare a Fixed Design, an Adaptive Design with early stopping, an ADORE-like Adaptive RAR Design, and two new Hybrid Designs with different hyperpriors. DISCUSSION: Simulation reveals several advantages of the RAR designs, such as higher allocation to the more promising dose and a trial duration reduction. The proposed Hybrid RAR Designs addresses the statistical power drop observed in Adaptive RAR. The new design model shows robustness to hyperprior choices. We recommend Hybrid RAR Design 1 for ADORE Precision, anticipating that it will yield precise determinations, which is crucial for advancing our understanding in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: xshi2@kumc.edu.
- Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
- Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.
Zitieren
APA
Shi, X., Wick, J. A., Christifano, D. N., Carlson, S. E., Brown, A. R., Mudaranthakam, D. P., & Gajewski, B. J. (2024). DHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107633
Vancouver
Shi X, Wick JA, Christifano DN, Carlson SE, Brown AR, Mudaranthakam DP, et al. DHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization. Contemporary Clinical Trials. 2024. doi:10.1016/j.cct.2024.107633
BibTeX
@article{Shi2024,
author = {Shi, Xiaosong and Wick, Jo A and Christifano, Danielle N and Carlson, Susan E and Brown, Alexandra R and Mudaranthakam, Dinesh Pal and Gajewski, Byron J},
title = {DHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization},
journal = {Contemporary Clinical Trials},
year = {2024},
doi = {10.1016/j.cct.2024.107633}
}
EUVIMED